
Zoetis Inc. company profile
$83.82+1.04%Close 13 Nov 2026
About Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures and commercializes animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health products. Its products cover eight core species, including dogs, cats, horses, cattle, swine, poultry, fish and sheep, and span categories such as parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion animal products represented approximately 70% of revenue in 2025 and livestock products approximately 29%. Customers include veterinarians, pet owners, livestock producers and third-party veterinary distributors. The company sells in more than 100 countries and directly markets its products in approximately 45 countries. The United States accounted for 54% of 2025 revenue.
A summary of the business section of the company's latest annual report, filed 12 Feb 2026.
Company facts
| Ticker | ZTS · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1555280 |
|---|
| Latest annual report | 10-K, filed 12 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Kristin C. Peck | Chief Executive Officer · Director | 493K | Option exercise, 19 Feb 2026 |
|---|
| Wetteny Joseph | Chief Financial Officer | 66.9K | Shares withheld for tax, 19 Feb 2026 |
|---|
| Roxanne Lagano | Executive Vice President | 50.2K | Option exercise, 19 Feb 2026 |
|---|
| Michael B. McCallister | Director | 39.9K | Gift, 10 Jun 2026 |
|---|
| Gregory Norden | Director | 29.1K | Gift, 9 Mar 2026 |
|---|
| Louise M. Parent | Director | 26.4K | Option exercise, 20 May 2026 |
|---|
| Paul M. Bisaro | Director | 25.9K | Open-market purchase, 13 May 2026 |
|---|
| Jamie Brannan | Executive Vice President | 23.4K | Shares withheld for tax, 19 Feb 2026 |
|---|
| Robert Polzer | Executive Vice President | 21.6K | Shares withheld for tax, 8 Feb 2025 |
|---|
| Willie M. Reed | Director | 17.9K | Option exercise, 19 Feb 2026 |
|---|
| Antoinette R. Leatherberry | Director | 6.8K | Option exercise, 19 Feb 2026 |
|---|
| Vanessa Broadhurst | Director | 3.9K | Option exercise, 19 Feb 2026 |
|---|
| Gavin D.K. Hattersley | Director | 3.4K | Option exercise, 19 Feb 2026 |
|---|
| FULLER JULIE | Executive Vice President | — | Option exercise, 30 Sep 2026 |
|---|
| DAMELIO FRANK A | Director | — | Gift, 7 Aug 2026 |
|---|
| Mark Stetter | Director | — | Option exercise, 21 May 2026 |
|---|
| Esch Kevin | Executive Vice President | — | Option exercise, 30 Apr 2026 |
|---|
| Sarbaugh Keith | Executive Vice President | — | Option exercise, 31 Mar 2026 |
|---|
| Ashton Nicholas | Executive Vice President | — | Shares withheld for tax, 19 Feb 2026 |
|---|
| Driscoll Rimma | Executive Vice President | — | Shares withheld for tax, 19 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ZTS in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.